Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 7/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25348299 | 1.00 | ATM (0.48) | ATMCTSKCTSLCTSBPREP | |
| SCHEMBL4448935 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBPREPCMA1 | |
| SCHEMBL4448932 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBPREPCMA1 | |
| SCHEMBL3047503 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBPREPCMA1 | |
| SCHEMBL3047502 | 0.89 | CTSL (0.44) | CTSKCTSLCTSBPREPCMA1 | |
| SCHEMBL30856518 | 0.89 | ATM (0.51) | ATMHDAC8ELANE | |
| SCHEMBL24441116 | 0.88 | CTSL (0.43) | CTSKCTSLCTSBPREPCMA1 | |
| SCHEMBL1981800 | 0.87 | ATM (0.53) | ATM | |
| SCHEMBL13318867 | 0.86 | ATM (0.49) | ATMELANE | |
| SCHEMBL806127 | 0.86 | ATM (0.49) | ATMELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| CN-119630656-A | Heterocyclic compounds for inducing cleavage of mutant KRAS proteins | 安斯泰来制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025019819-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024261256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| EP-4476225-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2024-12-18 | — | — | EP | disclosed |
| CN-118871440-A | 3-Substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degrading agents | 奥瑞基尼肿瘤有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023152666-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-17 | — | — | WO | disclosed |
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | SMARCC1, SMARCC2, SMARCA4 | ATM 1100/4885CTSK 3894/4885CTSL 4495/4885 |
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | ATM 4221/4885CTSK 162/4885CTSL 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.